On April 18, 2026, the 12th annual Breakthrough Prize ceremony unfolded at Barker Hangar in Santa Monica, drawing a roster of Hollywood stars to celebrate scientific breakthroughs that often remain invisible to the public eye.
The event, dubbed the “Oscars of Science,” honored researchers across mathematics, fundamental physics, and life sciences, with the most tangible impact coming from the $3 million award shared by Dr. Swee Lay Thein of the National Heart, Lung and Blood Institute and Dr. Stuart H. Orkin of Harvard University. Their decades-long collaboration uncovered the genetic mechanism behind fetal hemoglobin reactivation, paving the way for Casgevy — the first CRISPR-based therapy approved to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Casgevy works by disabling the BCL11A gene, which suppresses fetal hemoglobin after birth. By reactivating this fetal form, the therapy effectively compensates for defective adult hemoglobin, reducing sickling and eliminating the necessitate for chronic blood transfusions in many patients. Thein, who began studying variations in disease severity in the 1980s, said she felt “extremely honored, overwhelmed and humbled” upon receiving the award — a sentiment echoed by Orkin, whose earlier work laid the foundation for understanding hemoglobin switching.
The therapy addresses a global burden: sickle cell disease affects an estimated 7 to 8 million people worldwide, predominantly in sub-Saharan Africa, where access to advanced medical care remains limited. In the U.S. And Europe, where Casgevy is now available, the one-time treatment carries a list price of approximately $2.2 million per patient, raising immediate questions about equity and scalability.
For more on this story, see Save Up to $500 on Disrupt 2026 Passes: Final 3 Days.
Meanwhile, the red carpet told a different story. Attendees included Jessica Chastain, Gal Gadot, Michelle Yeoh, Lily Collins, Ben Affleck, Robert Downey Jr., Octavia Spencer, Edward Norton, Salma Hayek, Olivia Wilde, Anne Hathaway, Gigi Hadid, and numerous other figures from film, fashion, and music. Their presence underscored the event’s dual identity — part scientific accolade, part celebrity spectacle — a juxtaposition that has develop into routine since the prize’s founding in 2012 by Yuri Milner, Mark Zuckerberg, and Sergey Brin.
This blending of worlds raises a quiet tension: while the Breakthrough Prize aims to elevate scientists to cultural prominence, the glare of celebrity often shifts focus from the research to the red carpet. Yet the visibility brought by stars like Hathaway and Hadid may serve a quieter purpose — drawing attention to diseases that disproportionately affect marginalized populations and rarely make headlines outside medical journals.
The contrast is stark: inside the hangar, scientists celebrated a breakthrough that could free thousands from lifelong pain and hospital visits; outside, cameras flashed on designer gowns and celebrity couples. Both narratives are true. One reflects the leisurely, meticulous work of basic science; the other, the culture’s need to ritualize achievement through spectacle.
What remains unresolved is whether this model — pairing high-profile entertainment with rigorous scientific recognition — ultimately advances public understanding of science or merely repackages it for mass consumption. For now, the prize continues to grow in prestige, its ceremonies drawing larger crowds each year, even as the therapies it honors move from laboratory to clinic, offering real relief to patients who have waited generations for a cure.
What is Casgevy and how does it work?
Casgevy is a CRISPR-based gene therapy that treats sickle cell disease and beta-thalassemia by disabling the BCL11A gene, which allows the body to resume production of fetal hemoglobin. This fetal form of hemoglobin prevents red blood cells from sickling, reducing painful crises and eliminating the need for regular blood transfusions in many patients.
Who won the 2026 Breakthrough Prize in Life Sciences?
Dr. Swee Lay Thein of the National Heart, Lung and Blood Institute and Dr. Stuart H. Orkin of Harvard University shared the $3 million prize for their foundational research that led to the development of Casgevy, the first approved CRISPR therapy for genetic blood disorders.